Earnings Feed
Start Free
Home/Filings/4/0001193125-26-011756
4//SEC Filing

Mulay James 4

Accession 0001193125-26-011756

CIK 0001991792other
View on SEC.govCompany Profile

Filed

Jan 12, 7:00 PM ET

Accepted

Jan 13, 4:15 PM ET

Size

13.1 KB

Accession

0001193125-26-011756

Insider Transaction Report

Form 4
Period: 2026-01-09
CG Oncology, Inc.CGON
Mulay James
Director
Transactions
  • Exercise/Conversion

    Common Stock

    2026-01-09$3.72/sh+654$2,433→ 654 total
  • Sale

    Common Stock

    [F1]
    2026-01-09$44.16/sh−654$28,881→ 0 total
  • Exercise/Conversion

    Common Stock

    2026-01-09$12.59/sh+10,491$132,082→ 10,491 total
  • Sale

    Common Stock

    [F1]
    2026-01-09$52.99/sh−10,491$555,918→ 0 total
  • Exercise/Conversion

    Director Stock Option (right to buy)

    [F2]
    2026-01-09−654→ 1,308 total
    Exercise: $3.72Exp: 2033-06-13→ Common Stock (654 underlying)
  • Exercise/Conversion

    Director Stock Option (right to buy)

    [F3]
    2026-01-09−10,491→ 5,240 total
    Exercise: $12.59Exp: 2033-12-12→ Common Stock (10,491 underlying)
Footnotes (3)
  • [F1]The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025.
  • [F2]The stock option vests in 36 substantially equal monthly installments beginning on July 14, 2023.
  • [F3]The stock option vests in 36 substantially equal monthly installments beginning on January 13, 2024.
Signature
/s/ Joshua F. Patterson, Attorney-in-Fact for James J. Mulay|2026-01-13

Documents

1 file

Issuer

CG Oncology, Inc.

CIK 0001991792

→
Entity typeother

Related Parties

1
  • filerCIK 0001684531

Filing Metadata

Form type
4
Filed
Jan 12, 7:00 PM ET
Accepted
Jan 13, 4:15 PM ET
Size
13.1 KB
View on SEC.gov